Keywords: affimed, antithrombotic, ab, completes, proof-of-concept, trial, germany
Affimed's antithrombotic Ab completes proof-of-concept trial
Article | 11 December 2006
Germany's Affimed, a privately-held biopharmaceutical firm focused on antibody therapeutics, says that it has completed an in vivo proof-of-concept trial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
